NASDAQ:LGND Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis $101.14 -2.01 (-1.95%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$99.08▼$104.8950-Day Range$82.70▼$110.1152-Week Range$49.24▼$112.13Volume64,658 shsAverage Volume144,861 shsMarket Capitalization$1.82 billionP/E Ratio19.56Dividend YieldN/APrice Target$131.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Ligand Pharmaceuticals alerts: Email Address Ligand Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside29.5% Upside$131.00 Price TargetShort InterestBearish5.89% of Shares Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews Sentiment0.89Based on 3 Articles This WeekInsider TradingSelling Shares$3.28 M Sold Last QuarterProj. Earnings Growth29.94%From $3.54 to $4.60 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.72 out of 5 starsMedical Sector45th out of 910 stocksPharmaceutical Preparations Industry15th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLigand Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Ligand Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.89% of the outstanding shares of Ligand Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently increased by 10.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLigand Pharmaceuticals has received a 67.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Pneumococcal vaccines", "Quinolones", "Fosphenytoin", "Antifungal medication (D01) ", and "Bevacizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Ligand Pharmaceuticals is -1.57. Previous Next 2.2 News and Social Media Coverage News SentimentLigand Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Ligand Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for LGND on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold 1,247.83% more of their company's stock than they have bought. Specifically, they have bought $243,475.00 in company stock and sold $3,281,620.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Ligand Pharmaceuticals is held by insiders.Percentage Held by Institutions91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ligand Pharmaceuticals' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to grow by 29.94% in the coming year, from $3.54 to $4.60 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 19.56, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 19.56, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.06.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ligand Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressEx-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…Click here now and learn how to prepare. About Ligand Pharmaceuticals Stock (NASDAQ:LGND)Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Read More LGND Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LGND Stock News HeadlinesAugust 31, 2024 | insidertrades.comInsider Selling: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells 1,500 Shares of StockAugust 27, 2024 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) COO Sells $122,109.78 in StockSeptember 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…August 14, 2024 | insidertrades.comMatthew E. Korenberg Sells 18,245 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockAugust 10, 2024 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) CEO Todd C. Davis Acquires 2,500 SharesSeptember 2, 2024 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $159,585.00 in StockAugust 30, 2024 | globenewswire.comCD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030August 29, 2024 | americanbankingnews.comInsider Selling: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) COO Sells $122,109.78 in StockSeptember 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…August 28, 2024 | americanbankingnews.comMatthew E. Korenberg Sells 11,389 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockAugust 28, 2024 | sg.finance.yahoo.comLigand Pharmaceuticals Incorporated (LGDN.F)August 27, 2024 | finance.yahoo.comInsider Sale: President & COO Matthew Korenberg Sells 18,858 Shares of Ligand ...August 20, 2024 | finance.yahoo.comLigand to Present at H.C. Wainwright 26th Annual Global Investment ConferenceAugust 18, 2024 | ca.finance.yahoo.comLGND Feb 2025 125.000 callAugust 18, 2024 | ca.finance.yahoo.comLGND Feb 2025 130.000 callAugust 18, 2024 | ca.finance.yahoo.comLGND Feb 2025 90.000 putAugust 15, 2024 | uk.investing.comLigand Pharmaceuticals exec sells over $1.7 million in company stockAugust 15, 2024 | msn.comLewis-base ligand optimized electrolyte composition enhances CO₂ electrolysis performanceSee More Headlines Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:LGND CUSIP53220K50 CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$131.00 High Stock Price Target$144.00 Low Stock Price Target$110.00 Potential Upside/Downside+29.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$5.17 Trailing P/E Ratio19.56 Forward P/E Ratio28.57 P/E GrowthN/ANet Income$52.15 million Net Margins29.69% Pretax Margin39.71% Return on Equity7.91% Return on Assets6.99% Debt Debt-to-Equity RatioN/A Current Ratio16.82 Quick Ratio15.81 Sales & Book Value Annual Sales$133.48 million Price / Sales13.64 Cash Flow$4.78 per share Price / Cash Flow21.15 Book Value$42.43 per share Price / Book2.38Miscellaneous Outstanding Shares18,000,000Free Float16,938,000Market Cap$1.82 billion OptionableOptionable Beta1.01 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Matthew E. Korenberg (Age 49)President & COO Comp: $831.77kMr. Octavio Espinoza (Age 53)Chief Financial Officer Comp: $613.59kMr. Andrew T. Reardon J.D. (Age 49)Chief Legal Officer & Secretary Comp: $614.87kMr. Scott M. Plesha (Age 59)Chief Executive Officer Mr. Paul J. HaddenSenior Vice President of Investments & Business DevelopmentSimon LatimerHead of Investor RelationsMr. Todd PettingillDirector of Corporate DevelopmentMs. Audrey Warfield-GrahamChief People OfficerDr. Keith MarschkeSenior Vice President of Biology & Scientific AffairsDr. Vincent D. Antle (Age 55)Senior Vice President of Technical Operations & QA - Capitsol More ExecutivesKey CompetitorsNurix TherapeuticsNASDAQ:NRIXPraxis Precision MedicinesNASDAQ:PRAXTravere TherapeuticsNASDAQ:TVTXArcturus TherapeuticsNASDAQ:ARCTCOMPASS PathwaysNASDAQ:CMPSView All CompetitorsInsiders & InstitutionsAndrew ReardonSold 1,500 sharesTotal: $159,585.00 ($106.39/share)Dana Investment Advisors Inc.Bought 14,210 shares on 8/27/2024Ownership: 0.500%Matthew E KorenbergSold 11,389 sharesTotal: $1.20 M ($105.61/share)Matthew E KorenbergSold 1,157 sharesTotal: $122,109.78 ($105.54/share)Susquehanna International Group LLPSold 7,400 shares on 8/16/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions LGND Stock Analysis - Frequently Asked Questions How have LGND shares performed this year? Ligand Pharmaceuticals' stock was trading at $71.42 on January 1st, 2024. Since then, LGND shares have increased by 41.6% and is now trading at $101.14. View the best growth stocks for 2024 here. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.06 by $0.34. Ligand Pharmaceuticals's revenue for the quarter was up 57.2% on a year-over-year basis. What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO? 1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Ligand Pharmaceuticals' major shareholders? Top institutional investors of Ligand Pharmaceuticals include Dimensional Fund Advisors LP (3.94%), Chicago Capital LLC (2.86%), Rice Hall James & Associates LLC (1.62%) and William Blair Investment Management LLC (1.13%). Insiders that own company stock include John L Higgins, Matthew W Foehr, Todd C Davis, Matthew E Korenberg, John W Kozarich, Stephen L Sabba, Octavio Espinoza, Andrew Reardon and Nancy Ryan Gray. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV) and Netflix (NFLX). This page (NASDAQ:LGND) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
